Definium Therapeutics (NASDAQ:DFTX) Insider Matthew Wiley Sells 3,097 Shares of Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Matthew Wiley sold 3,097 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $113,257.29. Following the transaction, the insider owned 359,036 shares in the company, valued at $13,129,946.52. The trade was a 0.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Stock Performance

Shares of DFTX stock traded down $0.20 on Tuesday, hitting $38.21. The company’s stock had a trading volume of 1,967,182 shares, compared to its average volume of 2,245,960. Definium Therapeutics, Inc. has a fifty-two week low of $10.46 and a fifty-two week high of $49.70. The company has a market capitalization of $5.13 billion, a PE ratio of -11.14 and a beta of 2.23. The stock’s 50 day moving average is $41.37 and its 200-day moving average is $32.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities research analysts expect that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Institutional Trading of Definium Therapeutics

Several large investors have recently made changes to their positions in the company. Nykredit A S bought a new position in Definium Therapeutics during the second quarter worth $45,000. Allworth Financial LP bought a new stake in Definium Therapeutics during the second quarter valued at $110,000. Integrated Wealth Concepts LLC bought a new stake in Definium Therapeutics during the second quarter valued at $159,000. NewEdge Advisors LLC acquired a new stake in Definium Therapeutics during the 2nd quarter worth about $222,000. Finally, WINTON GROUP Ltd acquired a new stake in Definium Therapeutics during the 2nd quarter worth about $240,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DFTX. Stifel Nicolaus boosted their price target on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Robert W. Baird increased their target price on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $66.00 price target on shares of Definium Therapeutics in a research report on Friday, September 11th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $64.88.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.